First-in-world approval of Dupixent for adults with uncontrolled COPD with raised blood eosinophils based on...
Kuehn Law Encourages Investors of Regeneron Pharmaceuticals, Inc. to Contact Law Firm PR Newswire NEW YORK...
TARRYTOWN, N.Y., June 28, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today...
TARRYTOWN, N.Y., June 27, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today...
Majority of patients in this age group with eosinophilic esophagitis (EoE) receiving Dupixent achieved...
At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response or better and...
Approval in patients with pJIA weighing 63kg or greater adds to Kevzara’s position in treating adult chronic...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.